View in EDS

Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101.

Saved in:
Bibliographic Details
Title: Long-term follow-up of patients with AL amyloidosis treated on a phase 1 trial of CAEL-101.
Authors: Hughes MS; Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Pan S; Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Chakraborty R; Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Raikhelkar J; Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Maurer MS; Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Mapara MY; Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Eisenberger A; Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Lentzsch S; Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY., Bhutani D; Department of Hematology-Oncology, Columbia University Irving Medical Center, New York, NY.
Source: Blood advances [Blood Adv] 2025 Oct 14; Vol. 9 (19), pp. 4946-4950.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2025016731